Taiho Oncology to Present Data at the 2025 ASCO Gastrointestinal Cancers Symposium
Taiho Oncology, Inc. announced today presentations at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), to be held ...
ascopubs.org25d
ASCO Guidelines
He emphasizes the importance of this first guideline from ASCO on anal squamous cell carcinoma for both clinicians and patients with stage I-III anal cancer, and ongoing research the panel is looking ...
pharmaphorum1mon
A European perspective on oncology: ASCO review
While 2015 was marked by great announcements in the field of immunotherapy – particularly in melanoma and non-small cell lung cancer (NSCLC), this year’s American Society of Clinical Oncology ...
pharmaphorum8d
ASCO: Grail’s cancer blood test ‘promising’ in UK trial
The results of the trial will be presented at the ASCO cancer congress tomorrow, and simultaneously published in The Lancet Oncology journal. The SYMPLIFY trial is one of two large-scale community ...
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced data from its ...
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III ...
Hosted on MSN10d
FDA approved drug achieves 100% remission for rectal cancer
The battle against rectal cancer has entered an extraordinary new phase with the advent of immunotherapy, offering hope to ...